第九届董事会第八次会议决议公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-37 江苏澳洋健康产业股份有限公司 第九届董事会第八次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假 记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）第九 届董事会第八次会议于 2025 年 11 月 22 日以通讯方式发出会议通知，于 2025 年 12 月 2 日下午在公司会议室以现场结合通讯方式召开。会议应出席董事 9 名， 实际出席会议董事 9 名。公司监事及高管列席了会议。会议由公司董事长沈学如 先生主持，符合《公司法》及公司《章程》的有关规定。会议经认真审议，通过 如下议案： 一、审议通过《关于提前换届选举第十届董事会非独立董事的议案》 鉴于公司控股股东变更，根据《公司法》和公司《章程》等有关规定，经公 司董事会提名委员会进行资格审查后，公司控股股东张家港悦升科技合伙企业 （有限合伙）（以下简称"悦升科技"）拟提名高彦、席国平、卢平、季超为公 司第十届董事会非独立董事候选人；经公司股东澳洋集团有限公司（以下简称"澳 ...

Group 1 - The core viewpoint of the news is that Aoyang Health has shown fluctuations in stock performance, with a year-to-date increase of 35.14% but a recent decline in the last five trading days by 5.58% [1] - As of November 25, Aoyang Health's stock price was 4.23 CNY per share, with a market capitalization of 3.239 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 3.5156 million CNY, with significant buying and selling activities noted [1] Group 2 - For the period from January to September 2025, Aoyang Health reported operating revenue of 1.36 billion CNY, a year-on-year decrease of 9.39%, while the net profit attributable to shareholders was 40.1137 million CNY, reflecting a year-on-year increase of 3.71% [2] - The company has a total of 58,300 shareholders as of September 30, which is a decrease of 10.91% from the previous period, while the average circulating shares per person increased by 12.24% to 13,121 shares [2] - Aoyang Health has cumulatively distributed dividends of 26.1 million CNY since its A-share listing, with no dividends distributed in the last three years [3]

关于持股5%以上股东及其一致行动人部分股份解除质押和股份质押的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-36 江苏澳洋健康产业股份有限公司 关于持股 5%以上股东及其一致行动人部分股份解除 质押和股份质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 一、股东股份解除质押的基本情况 股东名 称 是否为控股股东 或第一大股东及 其一致行动人 本次解除质 押股数(股) 占其所持 股份比例 占公司总 股本比例 质押起 始日 解除质 押日 质权人 质押用 途 澳洋集 团有限 公司 否 25,000,000 30.41% 3.26% 2024/11 /20 2025/1 1/21 中国光大 银行股份 有限公司 无锡分行 担保 | | | | | | | | | | 限合伙） | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 澳洋集团 有限公司 | 否 | 25,000,000 | 30.41% | 3.26% | 否 | 否 ...

Core Insights - The high-pressure oxygen chamber concept has seen a decline of 0.21%, ranking among the top declines in concept sectors as of the market close on November 13 [1] - Within the sector, companies like Innovation Medical and International Medicine experienced significant declines, while six stocks saw price increases, with Dahu Co., Aoyang Health, and Samsung Medical leading the gains [1] Market Performance - The top-performing concept sectors today include: - Fluorochemical concept: +4.50% - Organic silicon concept: +4.47% - Sodium-ion battery: +4.47% - Lead metal: +4.27% - Phosphorus chemical: +4.25% [2] - The high-pressure oxygen chamber sector experienced a net outflow of 149 million yuan, with eight stocks seeing net outflows [2] Fund Flow Analysis - The stocks with the highest net outflows in the high-pressure oxygen chamber sector include: - Samsung Medical: -60.80 million yuan - Innovation Medical: -57.39 million yuan - International Medicine: -12.53 million yuan [2] - Conversely, the stocks with the highest net inflows include: - Yingkang Life: +10.12 million yuan - Hangyang Co.: +9.74 million yuan [2] Stock Performance - Key stock performances in the high-pressure oxygen chamber sector: - Samsung Medical: +0.37%, turnover rate: 2.18% - Innovation Medical: -2.00%, turnover rate: 13.41% - International Medicine: -0.80%, turnover rate: 1.13% [2]

澳洋健康公告称，2025年9月15日，悦升科技与澳洋集团签署协议，澳洋集团将1.53亿股（占比20%） 转让给悦升科技，同时放弃5%表决权。11月6日，股份过户登记完成。本次权益变动后，控股股东由澳 洋集团变更为悦升科技，实际控制人由沈学如变更为张家港经开区管委会。财务顾问东吴证券核查认 为，本次权益变动实施程序合规，相关方依法规范运作，收购人履行承诺且未违反后续计划，公司未为 收购人及其关联方提供担保或借款。 ...

东吴证券股份有限公司 关于 江苏澳洋健康产业股份有限公司 详式权益变动报告书 东吴证券股份有限公司（以下简称"本财务顾问"）接受悦升科技的委托， 担任其本次权益变动的财务顾问。2025年9月16日，上市公司公告了《详式权益 变动报告书》。根据《上市公司收购管理办法（2025年修正）》第七十一条， 本财务顾问持续督导期为2025年9月16日至收购完成后12个月。澳洋健康于2025 年10月31日披露了2025年三季度报告。根据《上市公司收购管理办法》等法律 法规的规定，通过日常沟通，并结合澳洋健康定期报告，本财务顾问出具本持 续督导意见。 本持续督导意见不构成对上市公司的任何投资建议；投资者根据本持续督 导意见所做出的任何投资决策而产生的相应风险，本财务顾问不承担任何责任。 本财务顾问未委托或授权其他任何机构或个人提供在本持续督导意见中列载的 信息和对本持续督导意见做任何解释或者说明，同时本财务顾问提请投资者认 真阅读上市公司发布的2025年三季度报告及其他信息披露文件。 释义 之 声明 2025年三季度持续督导意见 2025年9月15日，张家港悦升科技合伙企业（有限合伙）（以下简称"悦升 科技"）与江苏澳洋健 ...

Core Viewpoint - Jiangsu Aoyang Health Industry Co., Ltd. has completed the transfer of 20% of its shares to Zhangjiagang Yuesheng Technology Partnership, marking a shift from private to local state-owned control, which may enhance its market position and client trust [1][2][3] Group 1: Share Transfer Details - Aoyang Health's original controlling shareholder, Aoyang Group, transferred 20% of its shares, totaling 153 million shares, at a price of 3.87 yuan per share, amounting to a total of 593 million yuan [1] - The transfer was officially completed on November 6, 2025, with the new controlling entity being Zhangjiagang Economic and Technological Development Zone Management Committee [1] Group 2: Financial Performance - In the first three quarters of 2025, Aoyang Health reported a net profit attributable to shareholders of 40.11 million yuan, a year-on-year increase of 3.71% [2] - The net profit for the third quarter reached 8.56 million yuan, a significant increase of 533.86% compared to the same period last year, marking a new high for recent years [2] Group 3: Strategic Implications of Control Change - The change in control to a local state-owned entity may provide Aoyang Health with enhanced credibility and trust from clients, particularly those with government collaboration interests [2] - The new controlling entity's diverse industry background could facilitate resource integration, potentially enhancing Aoyang Health's capabilities in areas like remote healthcare and smart health monitoring [3] - The shift aligns with national policies promoting integrated medical and elderly care, positioning Aoyang Health to leverage new market opportunities and improve competitive advantage [3]

Core Insights - The company has achieved significant growth in profitability, with a net profit of 8.56 million yuan in Q3 2025, marking a substantial increase of 533.86% year-on-year, reaching a new high for the same period in recent years [1] - For the first three quarters of 2025, the cumulative net profit attributable to shareholders reached 40.11 million yuan, reflecting a year-on-year growth of 3.71%, demonstrating strong operational resilience despite short-term revenue adjustments [1] - The company’s core business profitability has improved, with a net profit of 2.35 million yuan in Q3 2025, up 63.23% year-on-year, indicating a substantial enhancement in core business performance [1] Profitability and Efficiency - The gross profit margin for the first three quarters of 2025 remained stable at 14.27%, while the net profit margin in Q3 increased to 1.91%, up 1.57 percentage points year-on-year, showcasing improved profitability quality during revenue structure adjustments [2] - The company has established a medical consortium centered around Aoyang Hospital, with over 2,300 total beds, covering comprehensive medical and rehabilitation services, thus forming a strong competitive advantage in the regional healthcare market [2] Shareholding Changes - The company’s shareholding change has been a focal point, with the controlling shareholder, Aoyang Group, transferring 20% of its shares to Zhangjiagang Yuesheng Technology Co., Ltd. for a total price of 593 million yuan, which has been completed [3] - Following the change in control, the new shareholder is expected to provide policy resource support, expand financing channels, and enhance regional business collaboration, thereby optimizing the company’s governance structure and strengthening its capital base for future development [3]

江苏澳洋健康产业股份有限公司 关于控股股东协议转让股份完成过户登记暨公司控股股东、实际控制人变更的公告 证券代码：002172 证券简称：澳洋健康 公告编号：2025-34 关于控股股东协议转让股份完成过户登记暨公司 控股股东、实际控制人变更的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 江苏澳洋健康产业股份有限公司（以下简称"澳洋健康"或"公司"）于 今日收到张家港悦升科技合伙企业（有限合伙）（以下简称"悦升科技"）的通 知，获悉其协议转让公司股份事宜已完成过户登记手续。具体情况如下： 一、本次交易的基本情况 公司原控股股东澳洋集团有限公司（以下简称"澳洋集团"）、实际控制人 沈学如、实际控制人的一致行动人沈卿于 2025 年 9 月 15 日与张家港悦升科技合 伙企业（有限合伙）签署了《股份转让协议》。澳洋集团拟通过协议转让方式转 让公司 20%股份，共计 153,146,472 股。转让价格为 3.87 元/股，合计总金额为 592,676,846.64 元。 本次权益变动不构成关联交易，不触及要约收购。本次权益变动完成后，悦 升科技 ...

Group 1 - The core point of the article is that Aoyang Health announced the release of a portion of shares pledged by its major shareholder, Aoyang Group, amounting to 15,000,000 shares [2] Group 2 - Aoyang Group holds more than 5% of Aoyang Health's shares [2] - The announcement was made on the evening of November 6 [2]